Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES‐SCLC: A systematic review and network meta‐analysis of RCTs and RWSs

Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES‐SCLC: A systematic review and network meta‐analysis of RCTs and RWSs

Abstract Objectives To evaluate the efficacy and safety of programmed cell death 1 (PD‐1)/programmed cell death ligand 1 (PD‐L1) inhibitors in the treatment of extensive‐stage small‐cell lung cancer (ES‐SCLC), we conducted a systematic review and meta‐analysis that included randomized controlled tri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Runting Kang, Junling Ma, Bin Ai, Juanjuan Liu, Zitong Zheng, Jiangyong Yu
Format:	Article
Language:	English
Published:	Wiley 2024-11-01
Series:	Thoracic Cancer
Subjects:	elderly extensive stage small cell lung cancer immune checkpoint inhibitors meta‐analysis
Online Access:	https://doi.org/10.1111/1759-7714.15458
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
by: Eisaku Miyauchi, MD, PhD, et al.
Published: (2025-03-01)

Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients
by: Xiaoli Mu, et al.
Published: (2024-09-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024-12-01)

Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context
by: Jiacheng Yao, et al.
Published: (2025-03-01)

Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors
by: Pan Cheng, et al.
Published: (2024-12-01)

Immunotherapy for Extensive-stage Small Cell Lung Cancer:  Research Progress and Future Perspectives
by: Yuling ZHONG, et al.
Published: (2024-11-01)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01)

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis
by: Jiayi Tang, et al.
Published: (2024-11-01)

Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review
by: Huan Wang, et al.
Published: (2024-12-01)

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
by: Antoine Desilets, MD, MSc, et al.
Published: (2024-12-01)

Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy
by: Yi Ge, et al.
Published: (2024-12-01)

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
by: Huiping Qiang, et al.
Published: (2025-03-01)

The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy
by: Ya Zhang, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China
by: Caicong You, et al.
Published: (2024-12-01)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
by: Chee Khoon Lee, PhD, et al.
Published: (2025-02-01)

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials
by: Weiming Liang, et al.
Published: (2024-12-01)

Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer
by: Justin J. Kuhlman, et al.
Published: (2024-12-01)

Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge
by: Francesca Colonese, et al.
Published: (2024-11-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)

Current advances in immunotherapy for cancer
by: Indrajit Desai, et al.
Published: (2024-12-01)

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification
by: Liang Zheng, et al.
Published: (2024-09-01)

New developments in immunotherapy for SCLC
by: Zhonglin Hao, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer
by: Maojin You, et al.
Published: (2024-11-01)

Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials
by: Andrea Messori, et al.
Published: (2025-01-01)

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
by: Jumin Huang, et al.
Published: (2025-02-01)

Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
by: Lu Zheng, et al.
Published: (2025-01-01)

Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
by: Ying Liu, et al.
Published: (2024-01-01)

Radiotherapy in patients with brain metastases with and without concomitant immunotherapy: comparison of patient outcome and neurotoxicity
by: Natalie Elyan, et al.
Published: (2024-11-01)

Inflammatory markers predict efficacy of immunotherapy in advanced non-small cell lung cancer: a preliminary exploratory study
by: Yingqing Zhang, et al.
Published: (2025-01-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan
by: Qingqing Hu, et al.
Published: (2025-01-01)

Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China
by: Guanzhong Liang, et al.
Published: (2024-08-01)

Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer
by: Jenny Ling-Yu Chen, et al.
Published: (2024-11-01)

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
by: Guisen Yin, et al.
Published: (2025-01-01)

Immunotherapy against glioblastoma using backpack‐activated neutrophils
by: Tatsuya Fukuta, et al.
Published: (2025-01-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)